POLY MEDICURE 2020-21 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

POLY MEDICURE 2020-21 Annual Report Analysis
Wed, 20 Oct

POLY MEDICURE has announced its results for the year ended March 2021. Let us have a look at the detailed performance review of the company during FY20-21.

POLY MEDICURE Income Statement Analysis

  • Operating income during the year rose 14.4% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 30.3% YoY during the fiscal. Operating profit margins witnessed a fall and down at 27.5% in FY21 as against 24.2% in FY20.
  • Depreciation charges increased by 17.3% and finance costs decreased by 48.0% YoY, respectively.
  • Other income declined by 0.3% YoY.
  • Net profit for the year grew by 41.4% YoY.
  • Net profit margins during the year grew from 13.3% in FY20 to 16.5% in FY21.

POLY MEDICURE Income Statement 2020-21

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Net Sales Rs m 6,872 7,865 14.4%
Other income Rs m 185 184 -0.3%
Total Revenues Rs m 7,057 8,049 14.1%
Gross profit Rs m 1,661 2,165 30.3%
Depreciation Rs m 405 475 17.3%
Interest Rs m 205 106 -48.0%
Profit before tax Rs m 1,236 1,767 43.0%
Tax Rs m 298 442 48.0%
Profit after tax Rs m 937 1,326 41.4%
Gross profit margin % 24.2 27.5
Effective tax rate % 24.1 25.0
Net profit margin % 13.3 16.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



EV Stocks: Which is Tanushree's Top Pick?

POLY MEDICURE Balance Sheet Analysis

  • The company's current liabilities during FY21 down at Rs 2 billion as compared to Rs 2 billion in FY20, thereby witnessing an decrease of -4.6%.
  • Long-term debt down at Rs 633 million as compared to Rs 1 billion during FY20, a fall of 44.7%.
  • Current assets rose 114% and stood at Rs 7 billion, while fixed assets rose 15% and stood at Rs 5 billion in FY21.
  • Overall, the total assets and liabilities for FY21 stood at Rs 13 billion as against Rs 8 billion during FY20, thereby witnessing a growth of 59%.

POLY MEDICURE Balance Sheet as on March 2021

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Networth Rs m 4,347 9,648 122.0
 
Current Liabilities Rs m 2,255 2,151 -4.6
Long-term Debt Rs m 1,144 633 -44.7
Total Liabilities Rs m 7,995 12,674 58.5
 
Current assets Rs m 3,500 7,495 114.1
Fixed Assets Rs m 4,495 5,179 15.2
Total Assets Rs m 7,995 12,674 58.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



POLY MEDICURE Cash Flow Statement Analysis

  • POLY MEDICURE's cash flow from operating activities (CFO) during FY21 stood at Rs 1 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY21 stood at Rs -4 billion, an improvement of 306.1% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY21 stood at Rs 3 billion, an improvement of 1,646% on a YoY basis.
  • Overall, net cash flows for the company during FY21 stood at Rs 1 million from the Rs 5 million net cash flows seen during FY20.

POLY MEDICURE Cash Flow Statement 2020-21

Particulars No. of months 12 12 % Change
Year Ending Mar-20 Mar-21
Cash Flow from Operating Activities Rs m 1,283 1,187 -7.5%
Cash Flow from Investing Activities Rs m -1,073 -4,356 -
Cash Flow from Financing Activities Rs m -205 3,169 -
Net Cash Flow Rs m 5 1 -82.0%
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for POLY MEDICURE

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 13.8, an improvement from the EPS of Rs 10.6 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 929.9, stands at 62.1 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 5.6 times, while the price to sales ratio stands at 6.8 times.
  • The company's price to cash flow (P/CF) ratio stood at 49.5 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Sales per share (Unadj.) Rs 77.9 82.0
TTM Earnings per share Rs 10.6 13.8
Diluted earnings per share Rs 9.8 13.8
Price to Cash Flow x 61.1 49.5
TTM P/E ratio x 57.2 62.1
Price / Book Value ratio x 5.2 5.6
Market Cap Rs m 82,056 89,155
Dividends per share (Unadj.) Rs 2.0 2.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for POLY MEDICURE

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 3.5x during FY21, from 1.6x during FY20. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 17.6x during FY21, from 7.0x during FY20. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 13.7% during FY21, from 21.6% during FY21. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 18.2% during FY21, from 26.2% during FY20. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 11.3% during FY21, from 14.3% during FY20. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Current ratio x 1.6 3.5
Debtors’ Days Days 675 726
Interest coverage x 7.0 17.6
Debt to equity ratio x 0.3 0.1
Return on assets % 14.3 11.3
Return on equity % 21.6 13.7
Return on capital employed % 26.2 18.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how POLY MEDICURE has performed over the last 5 years, please visit here.

POLY MEDICURE Share Price Performance

Over the last one year, POLY MEDICURE share price has moved up from Rs 504.5 to Rs 929.9, registering a gain of Rs 425.4 or around 84.3%.

Overall, the S&P BSE SENSEX is up 52.2% over the year.

(To know more, check out historical annual results for POLY MEDICURE and quarterly results for POLY MEDICURE)

Equitymaster requests your view! Post a comment on "POLY MEDICURE 2020-21 Annual Report Analysis". Click here!

  

Related Views on News

POLY MEDICURE Announces Quarterly Results (1QFY22); Net Profit Up 42.0% (Quarterly Result Update)

Jul 31, 2021 | Updated on Jul 31, 2021

For the quarter ended June 2021, POLY MEDICURE has posted a net profit of Rs 369 m (up 42.0% YoY). Sales on the other hand came in at Rs 2 bn (up 24.4% YoY). Read on for a complete analysis of POLY MEDICURE's quarterly results.

Shares of Oxygen Suppliers in Focus Amid Rising Demand for Oxygen (Company Info)

Apr 20, 2021

In this article, we discuss the hype around Oxygen supplier stocks and a little known NBFC company, which has rallied 150% in less than a month.

Nazara Technologies IPO: Should You Apply? (IPO)

Mar 17, 2021

Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology(Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK POLY MEDICURE

  • Track your investment in POLY MEDICURE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

POLY MEDICURE 8-QTR ANALYSIS

COMPARE POLY MEDICURE WITH

MARKET STATS